> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher for Ultragenyx Pharma
- URL: https://www.fdaweb.com/priority-review-voucher-for-ultragenyx-pharma/
- Published: 2017-12-15T12:00:00.000Z
- Updated: 2026-09-14T23:09:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140361

*Federal Register* notice: FDA has announced the issuance of a priority review voucher to Ultragenyx Pharmaceutical for obtaining approval of a rare pediatric disease product — Mepsevii (vestronidase alfa-vjbk), indicated for treating Mucopolysaccharidosis Type VII. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-12-15/pdf/2017-27049.pdf?ref=fdaweb.com).